U.S. Food and Drug Administration, Office of Orphan Products Development announces the availability of funding for implementation of the Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01). The purpose of this grant is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. Contractors should refer to Section VII, Agency Contacts in the RFP, for information regarding each organization's grants management contact for this program . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

RFP | December 11, 2012

Federal Government Announces Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01) Funding

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member